

Under the Auspices of



SIE
Società Italiana di
Ematologia



PRESIDENTS

C. Cerchione, G. Martinelli

SCIENTIFIC BOARD

C. Cerchione, N. Daver, C. diNardo,
A. Ferrajoli, N. Fowler, G. Garcia-Manero,
E. Jabbour, H. Kantarjian, H. Lee, T. Kadia,
M. Konopleva, G. Martinelli, A. Ravandi

SCIENTIFIC SECRETARIAT

C. Cerchione, G. Martinelli,
G. Musuraca, S. Ronconi

In association with



1st ITALIAN CONFERENCE

25th - 26th September 2019
Crowne Plaza Rome St. Peter's, Rome - Italy

1st DAY 1 — 25th SEPTEMBER 2019

OPENING SESSION

- 08.15 Welcome – **C. Cerchione, G. Martinelli**
- 08.30 Welcome and Introduction – What is Italian SOHO
**C. Cerchione, G. Martinelli, N. Daver, E. Jabbour,
H. Kantarjian, M. Konopleva**

SESSION 1 - NEW DRUGS IN ACUTE MYELOID LEUKEMIAS SESSION CHAIRS - C. CERCHIONE, H. KANTARJIAN

- 08.45 AML: State of the art update in MD Anderson Cancer Center – **H. Kantarjian**
- 09.00 Novel Therapies in AML in MDACC - **N. Daver**
- 09.15 New drugs in AML in Europe – **G. Martinelli**
- 09.30 MDACC Approach To Treatment of older - **T. Kadia**
- 09.45 Current approach in elderly AML in Italy - **A. Isidori**
- 10.00 What is the role of allogenic transplant in AML in target therapy era? - **A. Rambaldi**

SESSION 2 - TARGET THERAPIES IN ACUTE MYELOID LEUKEMIAS SESSION CHAIRS - G. MARTINELLI, C. MECUCCI

- 10.15 Is this a new era for target therapies in AML?
M.P. Martelli
- 10.30 Novel venetoclax based therapies and mechanisms of resistance - **M. Konopleva**
- 10.45 Venetoclax in elderly AML - **C. diNardo**
- 11.00 FLT3-based approaches in AML - **N. Daver**
- 11.15 Role of CPX-351 in Acute Myeloid Leukemia
G. Martinelli
- 11.30 Should All Older AML Patients and Younger Patients with Adverse Biology Routinely Receive HMA/Venetoclax Instead of 3+7/Standard Induction? Whem Midostaurin? - **F. Ferrara**
- 11.45 Coffee break

SESSION 3 - NEW FRONTIERS IN ACUTE MYELOID LEUKEMIAS SESSION CHAIRS - A. RAMBALDI - B. FALINI

- 12.00 NPM1 AML: from bench to bed-side - **B. Falini**
- 12.15 NPM1 AML: new frontiers - **L. Brunetti**
- 12.30 Genotyping profiling in Acute Myeloid Leukemia in novel agents era - **G. Visani**
- 12.45 Environment-mediated drug resistance in AML
C. Cerchione
- 13.00 Role of MRD in AML - **M. Gottardi**
- 13.15 The assesment of MRD versus that of somatic mutations for predicting the outcome of Acute Myeloid Leukemia
M. Petrini
- 13.30 Lunch

SESSION 4 - BIOLOGY OF ACUTE MYELOID LEUKEMIAS SESSION CHAIRS - A. BOSI - M. GOBBI

- 14.15 Metabolism of Acute Myeloid Leukemia - **G. Simonetti**
- 14.30 Functional genomics and therapeutic targeting of Acute Erythroid Leukemia - **I. Iacobucci**
- 14.45 Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with Acute Myeloblastic Leukemia
R.M. Lemoli
- 15.00 Present and near future of AML trials in Italy - **A. Venditti**

SESSION 5 - NEW FRONTIERS IN MYELODYSPLASTIC SYNDROMES AND RARE DISEASES SESSION CHAIRS - E. JABBOUR - G. GARCIA-MANERO

- 15.15 Lecture: Advancing Leukemia diagnostics: Role of NGS in AML/MDS - **T. Haferlach**
- 15.30 State of art Update in MDACC: Emerging Targeted Therapeutics for MDS - **G. Garcia-Manero**
- 15.45 How I manage MDS in Italy - **V. Santini**
- 16.00 Progress in Targeting the TGFb Pathway, Managing TP53-Mutant MDS and Novel Chromatin modulation Strategies - **M. Dalla Porta**
- 16.15 How I treat Systematic Mastocytosis - **C. Papayannidis**

SESSION 6 - NEW FRONTIERS IN CHRONIC MYELOID LEUKEMIA AND MPNS SESSION CHAIRS - E. JABBOUR - G. SAGLIO

- 16.30 CML in MDACC: Management of resistant and advanced phase disease; optimizing TKIs and novel strategies
E. Jabbour
- 16.45 How I manage CML in Italy: First, Second and Third generations TKIs - **G. Saglio**
- 17.00 TFR: Impact of depth and Duration of Response - **D. Russo**
- 17.15 New insights into biology of MPN - **A.R. Migliaccio**
- 17.30 Coffee break

SESSION 7 - STATE OF THE ART OF LYMPHOMAS SESSION CHAIRS - N. FOWLER - G. MUSURACA

- 17.45 Lymphomas : State of the Art in MDACC - **N. Fowler**
- 18.00 Lymphomas: State of art in Italy - **G. Musuraca**
- 18.15 New frontiers in relapsed/refractory Hodgkin Lymphoma: role of brentuximab vedotin and nivolumab
A. Pinto

SESSION 8 - THE NEAR FUTURE OF LYMPHOMAS SESSION CHAIRS - M. MARTELLI - G. PAGANELLI

- 18.30 New frontiers in Aggressive Non- Hodgkin Lymphomas
M. Martelli
- 18.45 Microenvironment-driven metabolic rewiring in Hodgkin disease - **A. Romano**
- 19.00 CAR-T in Lymphomas - **C. Carlo-Stella**
- 19.15 Present and future of Lymphomas: How I will treat
A. Santoro
- 19.30 Conclusions Day 1 - **C. Cerchione, G. Martinelli**

DAY 2 — 26th SEPTEMBER 2019

EXTRA SESSION - BREAKFAST WITH THE EXPERT SESSION (max 10/expert)

- 08.00 Breakfast with the expert: Immunotherapy in AML – **N. Daver**
- 08.00 Breakfast with the expert: State of the art of CLL in MDACC – **A. Ferrajoli**
- 08.00 Breakfast with the expert: State of the art of Lymphomas in MDACC – **N. Fowler**
- 08.00 Breakfast with the expert: State of the art of MDS in MDACC – **G. Garcia-Manero**
- 08.00 Breakfast with the expert: CML in 2019: are we in "cure" era? – **E. Jabbour**
- 08.00 Breakfast with the expert: State of the art of older AML in MDACC – **T. Kadia**
- 08.00 Breakfast with the expert: State of the art of AML in MDACC – **H. Kantarjian**
- 08.00 Breakfast with the expert: New frontiers in biology of acute leukemias – **M. Konopleva**
- 08.00 Breakfast with the expert: Ph-like ALL and MRD in ALL/AML: Hematopathology perspective – **S. Konoplev**
- 08.00 Breakfast with the expert: State of the art of MM in MDACC – **H. Lee**
- 08.00 Breakfast with the expert: State of the art of ALL in MDACC – **A. Ravandi**

SESSION 9 - NEW FRONTIERS IN HEALTH MANAGEMENT SESSION CHAIRS - D. AMADORI, M. ALTINI (Italian Session)

- 08.30 Clinical trials management: present and future
Gestione dei trials clinici: presente e futuro
O. Nanni
- 08.45 New frontiers in Health management
Nuove frontiere nell'health management
M. Altini
- 09.00 Role of registries in Italy: importance for present and future
Ruolo dei registri in Italia: importanza per il presente e per il futuro – **E. Crocetti**
- 09.15 Drug Management in Italy: near future of OncoPharmacist
Drug Management in Italia: il futuro del farmacista Oncologico – **C. Masini**
- 09.30 My life against cancer
"Anima e coraggio. La mia vita contro il cancro"
D. Amadori
- 09.45 Multidisciplinary approach in IRST OncoHematology Department - L'approccio multidisciplinare nel reparto di OncoEmatologia IRST - **G.L. Frassinetti**

SESSION 10 - STATE OF THE ART IN ACUTE LYMPHOBLASTIC LEUKEMIAS SESSION CHAIRS - M. KONOPLEVA, A. RAVANDI

- 09.45 ALL: State of the art in MD Anderson Cancer Center – **H. Kantarjian**
- 10.45 How I manage Ph pos and Ph neg ALL in Italy – **C. Papayannidis**
- 10.15 Biology of ALL – Ph-like and Early T-cell precursor – **M. Konopleva**
- 10.30 MRD in ALL – **A. Ravandi**
- 11.00 Targeted therapy for ALL – **M. Vignetti** TBC
- 11.15 Infections in Acute Leukemias – **L. Pagano**
- 11.30 Morphology in Acute Leukemias and hematologic malignancies – **G. Zini**
- 11.45 Coffee break

SESSION 11 - NEW FRONTIERS IN ACUTE LYMPHOBLASTIC LEUKEMIA SESSION CHAIRS - F. LOCATELLI, G. MARTINELLI

- 12.00 Triple negative B-ALL – **A. Ferrari**
- 12.15 Novel therapeutic strategies on acute leukemia based on synthetic lethality
A. Ghelli
- 12.30 Childhood ALL: How To Cure the Very High Risk – Role of CAR-T – **F. Locatelli**
- 12.45 CAR-T clinical trials for patients with Leukemia or Lymphoma: room for improvement
C. Quintarelli
- 13.00 Ph + ALL: How Can we optimize treatment for all patients? – **E. Jabbour**
- 13.15 Present and Future of GIMEMA Trials in ALL
S. Chiaretti
- 13.30 Lunch

SESSION 12 - THE NEAR FUTURE OF MULTIPLE MYELOMA AND MGUS SESSION CHAIRS - C. CERCHIONE, H. LEE

- 14.15 MM: State of the art in MD Anderson Cancer Center – **H. Lee**
- 14.30 MM: State of the art in Italy – **C. Cerchione**
- 14.45 Biology of MM, SMM and MGUS – **C. Terragna**
- 15.00 Importance of imaging in multiple myeloma in era of novel agents – **E. Zamagni**
- 15.15 Old and new generation drugs and newest combinations: PIs, IMiDs and monoclonal antibodies: carfilzomib, ixazomib, pomalidomide, daratumumab, elotuzumab and beyond
V. Montefusco

SESSION 13 - THE NEAR FUTURE OF MULTIPLE MYELOMA AND MGUS SESSION CHAIRS - M. BOCCADORO, P. TOSI

- 15.30 New Insights in Anti-Angiogenesis in Multiple Myeloma – **A. Vacca**
- 15.45 Autologous transplant in MM: towards a new era? – **M.T. Petrucci**
- 16.00 Novel agents role and use in frail patients
D. Derudas
- 16.15 Managing side effects in novel agents era
P. Tosi
- 16.30 Risk stratification of Multiple Myeloma in novel agents era – **F. Di Raimondo**
- 16.45 The importance of Real World evidence in Multiple Myeloma – **M. Boccardo**
- 17.00 Coffee break

SESSION 14 - NEW FRONTIERS IN CHRONIC LYMPHOCYTIC LEUKEMIA SESSION CHAIRS - A. FERRAJOLI, G. GAIDANO

- 17.15 CLL: State of the art update in MD Anderson Cancer Center – **A. Ferrajoli**
- 17.30 How I manage CLL in Italy – **A. Cuneo**
- 17.45 Role of MRD in CLL – **M. Massaia**
- 18.00 Genetics and Clonal Evolution in CLL – **P. Ghia**
- 18.15 Biology and treatment of Richter syndrome
G. Gaidano

CLOSING SESSION: NEXT QUESTIONS THE NEAR FUTURE OF HEMATOLOGY

- 18.30 The near future of Hematology in MDAAC and IRST – **H. Kantarjian, G. Martinelli**
- 18.45 Conclusions and Presentation of MD Anderson SOHO Italy Society:
See you in September 2020
C. Cerchione – G. Martinelli

Pro eventi PROVIDER ECM 2773
info@proeventi.it
0882.242151

N. 2773-268407: 12.6 ECM for 150 participants

Physicians, Pharmacists, Biologists, Biomedical Laboratory Technicians

Supported by an unrestricted educational grant from

